Dosing Considerations for Antibodies Against COVID-19

Area of Science:

• Pharmacology
• Immunology
• Virology

Background:

• No definitive cure for COVID-19 exists; treatments including immunoglobulins are under investigation.
• Understanding drug behavior in the body (pharmacokinetics) is vital for optimizing treatment.

Purpose of the Study:

• To explore how pharmacokinetic and viral load analyses can inform immunoglobulin dosing for COVID-19.
• To guide the development and dosing of hyperimmune anti-SARS-CoV-2 immunoglobulin.

Main Methods:

• Review of pre-clinical and clinical literature on antibody treatment with high antigen loads.
• Analysis of pharmacokinetic data, including antibody clearance and half-life.
• Illustration with examples of high viral and tumor loads impacting antibody clearance.

Main Results:

• High antigen loads (viral, bacterial, or tumor) accelerate antibody clearance and reduce their effectiveness (area under the curve, half-life).
• Pharmacokinetic parameters and antigen load influence antibody clearance rates.

Conclusions:

• A dosing strategy involving initial high doses and adjusted intervals based on pharmacokinetics can manage high antigen loads.
• COVID-19 immunoglobulin therapy requires careful consideration of viral load, antibody-virus interactions, and pharmacokinetic-based dose adjustments.